Combined Usage of Navitoclax and A-1210477 to Treat AcuteLymphoblastic Leukemia

Abstract

Mcl-1 protein has been a key targeted therapeutic protein in treating acute lymphoblastic leukemia because of its
resistance to other previously known drugs. However, a newly synthesized chemical A-1210477 has proven to possess
enough affinity to bind to the Mcl-1 protein and disrupt its normal function. As a result, scientists started to test the
potency of A-1210477 combined with other drugs to treat various cancers. This study will examine the effect of
A-1210477 and Bcl-2 inhibitor navitoclax combined to treat acute lymphoblastic leukemia Bal-KHc cell line both in
vitro by MTT and Annexin V/PI Facs as well as in vivo by measuring the tumor volume in xenograft.